培美曲塞二线治疗老年晚期非小细胞肺癌的疗效分析  

Clinical Analysis of Pemetrexed in the Treatment of Elderly Patients With Advanced Non-small Cell Lung Cancer

作　　者：王先国[1] 周远[1] 张山燕 李宇[1] 

机构地区：[1]山东省泰安市肿瘤防治院化疗二科,山东泰安271000

出　　处：《中国继续医学教育》2017年第12期178-179,共2页China Continuing Medical Education

摘　　要：目的探讨对晚期非小细胞肺癌老年患者行以培美曲塞二线治疗的临床效果。方法将2014年1月—2016年1月我院收治的38例晚期非小细胞肺癌患者作为研究对象,所有患者均接受500 mg/m^2的培美曲塞,第1天采取静脉注射的方式,3周为1个疗程。2个疗程后对患者的治疗效果以及所发生的不良反应进行回顾性分析。结果经过培美曲塞二线治疗后的总体有效率为9例(23.68%),疾病的总体控制率为20例(52.63%),中位疾病的进展(TTP)时间大约为3个月左右,不良反应主要表现为乏力以及抑制骨髓等。结论对晚期非小细胞肺癌老年患者行以培美曲塞二线治疗,能够减轻不良反应的同时,提高患者的耐受性和生活质量,治疗效果显著,值得用于非小细胞肺癌的治疗过程中。Objective To investigate the clinical efficacy of pemetrexed second-line therapy in elderly patients with advanced non-small cell lung cancer. Methods 38 cases of advanced non-small cell lung cancer patients treated in our hospital from January 2014 to January 2016 were selected as the subjects, all patients received pemetrexed 500 mg/m^2, on the first day by intravenous injection, and three weeks for a course of treatment. The therapeutic effect and adverse reactions of the patients after two courses were analyzed retrospectively. Results The overall effective rate after pemetrexed second-line treatment was 9 cases （23.68%）, the overall rate of disease control was 20 cases （52.63%）, the median disease progression （TTP） time was about 3 months, the main adverse reactions were fatigue and suppression of bone marrow. Conclusion For advanced non-small cell lung cancer in elderly patients with pemetrexed as second-line treatment can reduce the adverse reaction and improve patient tolerance and quality of life, the treatment effect is significant, worthy for the treatment of non-small cell lung cancer.

关 键 词：培美曲塞 二线治疗 老年 晚期 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]